CLINICAL TRIALS PROFILE FOR DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER

All Clinical Trials for Diflucan In Dextrose 5% In Plastic Container

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	Blood and Marrow Transplant Clinical Trials Network	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Cancer Institute (NCI)	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	National Marrow Donor Program	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00075803 ↗	Comparison of Fluconazole vs Voriconazole to Treat Fungal Infections for Blood and Marrow Transplants (BMT CTN 0101)	Completed	Medical College of Wisconsin	Phase 3	2003-11-01	The study is designed as a Phase III, randomized, double-blind, multicenter, prospective, comparative study of fluconazole versus voriconazole for the prevention of fungal infections in allogeneic transplant recipients. Recipients will be stratified by center and donor type (sibling vs. unrelated) and will be randomized to either the fluconazole or voriconazole arm in a 1:1 ratio.
NCT00166166 ↗	Endothelial Hyperpolarization in Humans	Terminated	National Heart, Lung, and Blood Institute (NHLBI)	Phase 2	2002-07-01	The purpose of this study is to elucidate the role Endothelium-Derived Hyperpolarizing Factor (EDHF) plays in dilating blood vessels and whether it differs between healthy people and those with high cholesterol. A second purpose of the study is to determine the identity of EDHF.

Clinical Trial Conditions for Diflucan In Dextrose 5% In Plastic Container

Condition Name

Condition Name for Diflucan In Dextrose 5% In Plastic Container
Intervention	Trials
Candidiasis	5
Fungal Infection	4
Healthy	3
Cryptococcal Meningitis	3

Condition MeSH

Condition MeSH for Diflucan In Dextrose 5% In Plastic Container
Intervention	Trials
Candidiasis	14
Mycoses	9
Infections	5
Infection	5

Clinical Trial Locations for Diflucan In Dextrose 5% In Plastic Container

Trials by Country

Trials by Country for Diflucan In Dextrose 5% In Plastic Container
Location	Trials
United States	157
Canada	14
Brazil	5
Spain	4
Italy	4

Trials by US State

Trials by US State for Diflucan In Dextrose 5% In Plastic Container
Location	Trials
California	9
North Carolina	8
Florida	8
Texas	8
Pennsylvania	8

Clinical Trial Progress for Diflucan In Dextrose 5% In Plastic Container

Clinical Trial Phase

Clinical Trial Phase for Diflucan In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Phase 4	7
Phase 3	11
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Diflucan In Dextrose 5% In Plastic Container
Clinical Trial Phase	Trials
Completed	27
Not yet recruiting	4
Unknown status	3

Clinical Trial Sponsors for Diflucan In Dextrose 5% In Plastic Container

Sponsor Name

Sponsor Name for Diflucan In Dextrose 5% In Plastic Container
Sponsor	Trials
Pfizer	4
Astellas Pharma Inc	3
National Cancer Institute (NCI)	3

Sponsor Type

Sponsor Type for Diflucan In Dextrose 5% In Plastic Container
Sponsor	Trials
Other	45
Industry	25
NIH	10

Last updated: May 24, 2026

DIFLUCAN IN DEXTROSE 5% IN PLASTIC CONTAINER (fluconazole IV) — Clinical Trials Update, Market Analysis, and Price/Revenue Projections

Executive summary: Diflucan in Dextrose 5% in Plastic Container is an IV formulation of fluconazole (brand name “Diflucan” for the active ingredient). Fluconazole’s clinical evidence base is mature, and commercial drivers are tied to hospital antifungal utilization, IV-to-oral stepdown practices, and formulary access. A “clinical trials update” for this exact packaged IV combination cannot be compiled without drug-specific trial identifiers (NCT numbers, comparative arms, or protocol publications) and current regulatory/Orange Book listing detail for the specific dosage form and container.

If you cannot validate: (1) which manufacturer/label version corresponds to “in dextrose 5% in plastic container,” (2) whether the product is FDA-approved as a specific NDA/BLA/strength-container configuration, and (3) the current status of any ongoing trials tied to that specific product, then any timeline and pipeline summary would risk being inaccurate.

Because the required source-level facts are not present in the input, no reliable clinical update, market sizing model, or projections can be produced.